Physician profile
Jonathan Benjamin
NPI 1558332072
$2,410.69
in general payments reported to CMS, 2019-2025
24 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $14.18 · 2021: $231 · 2022: $146 · 2023: $479 · 2024: $437 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $355.31 | 2019-2025 | Idosetr |
| Alcon Vision LLC | $342.17 | 2019-2025 | Clareon, Tryptyr, Simbrinza |
| Tarsus Pharmaceuticals, INC. | $293.89 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $162.37 | 2022-2023 | Cequa, Xelpros |
| Kala Pharmaceuticals, INC. | $161.77 | 2019-2021 | |
| Genentech USA, INC. | $148.68 | 2023-2025 | Vabysmo |
| Abbvie INC. | $140.24 | 2022-2024 | Vuity, Lumigan, Alphagan P |
| Recordati_rare_diseases_inc. | $122.19 | 2024 | Cystadrops |
| Allergan, INC. | $121.56 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $89.06 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $78.69 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Horizon Therapeutics Plc | $72.93 | 2021-2023 | Tepezza |
| Amgen INC. | $49.11 | 2024 | Tepezza |
| Harrow Eye, LLC | $46.70 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $34.03 | 2023-2024 | Dextenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $32.80 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30.28 | 2019-2021 | |
| Rxsight INC | $27.54 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $23.56 | 2023 | Tearcare System |
| Rayner Intraocular Lenses Limited | $16.99 | 2025 | Rayner Cataract Set 1, Rayone Aspheric, Rayone Spheric |
| Eyevance Pharmaceuticals LLC | $15.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.79 | 2023 | |
| Omeros Corporation | $15.01 | 2021 | |
| Biotissue Holdings INC. | $14.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.